Charcot-Marie-Tooth disease, also known as hereditary motor and sensory neuropathy, is a group of inherited disorders that cause damage to the peripheral nervous system. The disease causes the loss of muscle tissue and touch sensation and symptoms include weak leg and foot muscles, dropped foot, foot deformities, and difficulty with movements of the hands and feet. It affects around 1 in 2,500 people globally. Due to increase in prevalence of the disease and lack of effective treatment options, diagnosis has gained utmost importance.
Market key trends:
Increased research on disease pathophysiology and development of advanced diagnostics tests for accurate diagnosis are key trends coinciding with the market growth. Advancements such as development of high resolution MRI and ultrasound imaging techniques have enabled earlier detection and diagnosis of the disease. These techniques help in visualization of structural changes in nerves and muscles facilitating prompt treatment planning. Furthermore, identification of over 30 CMT associated genes has enabled development of genetic tests to confirm clinical diagnosis. Rise in funding for research from private and government organizations is expected to further fuel development of novel diagnostics and accelerate market growth over the forecast period.
Segment Analysis
The global Charcot-Marie-Tooth disease market is dominated by HNPP segment. HNPP segment accounts for over 35% of the total market share owing to highest prevalence of this type of Charcot-Marie-Tooth disease. HNPP is caused by duplication of the PMP22 gene which is a major peripheral myelin protein gene. Duplication of PMP22 gene results in overproduction of PMP22 protein leading to formation of myelin sheath with abnormal compacted structure thereby hampering proper nerve conduction.
Key Takeaways
Global Charcot-Marie-Tooth Disease Market Size is expected to witness high growth over the forecast period.
Regional analysis: North America holds dominant share in the global Charcot-Marie-Tooth disease market. Presence of sophisticated healthcare facilities and health insurance coverage for neurodegenerative disorders has contributed to North America's leadership position in the market. Asia Pacific is anticipated to witness fastest CAGR during the forecast period owing to rising healthcare spending, increasing incidence of Charcot-Marie-Tooth disease and growing medical tourism in countries such as India and China.
Key players operating in the Charcot-Marie-Tooth disease market are AveXis Inc., RegeneRx Biopharmaceuticals, Inc., AB Science S.A., Nemus Bioscience, Inc., Affectis Pharmaceuticals AG, Pharnext SAS, Lead Discovery Center GmbH, and Benitec Biopharma.
Explore More Related Article On This Topic: https://www.ukwebwire.com/the-charcot-marie-tooth-disease-market-is-driven-by-increasing-research/
Explore More Related Article: https://cmiresearch.blogspot.com/2024/01/the-global-training-market-growth.html
Comments
0 comment